Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis

Int J Mol Sci. 2023 Oct 6;24(19):14942. doi: 10.3390/ijms241914942.

Abstract

The rapid spread of drug-resistant M. tuberculosis (Mtb) strains and the phenomenon of phenotypic tolerance to drugs present challenges toward achieving the goal of tuberculosis (TB) elimination worldwide. By using the ex vivo cultures of alveolar macrophages obtained from lung tissues of TB patients after intensive antimicrobial chemotherapy before surgery, different subpopulations of multidrug-tolerant Mtb with a spectrum of phenotypic and growth features were identified in the same TB lesions. Our results are indicative of not only passive mechanisms generating nonheritable resistance of Mtb to antibiotics, which are associated mainly with a lack of Mtb growth, but also some active mechanisms of Mtb persistence, such as cell wall and metabolic pathway remodeling. In one of the subpopulations, non-acid-fast Mtb have undergone significant reprogramming with the restoration of acid-fastness, lipoarabinomannan expression and replication in host cells of some patients after withdrawal of anti-TB drugs. Our data indicate the universal stress protein Rv2623 as a clinically relevant biomarker of Mtb that has lost acid-fastness in human lungs. The studies of Mtb survival, persistence, dormancy, and resumption and the identification of biomarkers characterizing these phenomena are very important concerning the development of vaccines and drug regimens with individualized management of patients for overcoming the resistance/tolerance crisis in anti-TB therapy.

Keywords: Mycobacterium tuberculosis; Rv2623; alveolar macrophages; biomarkers; dormancy; drug tolerance; non-acid-fastness; persistence; pulmonary tuberculosis.

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Humans
  • Macrophages, Alveolar / pathology
  • Mycobacterium tuberculosis*
  • Tuberculosis* / microbiology
  • Tuberculosis, Pulmonary* / microbiology

Substances

  • Antitubercular Agents

Grants and funding

This research was carried out according to the State Budgeted Project no. 1021050400914-1-1.6.4 of the Ministry of Science and Higher Education of the Russian Federation for the Federal Research Center of Fundamental and Translational Medicine. This research received no external funding. The work was performed using the equipment of the Centers for Collective Use “Spectrometric Measurements” and “Proteomic Analysis”, supported by funding from the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075-15-2021-691).